Repare Therapeutics cae 2,25% a su mínimo de 12 meses ante la incertidumbre estratégica *Los factores principales: la oferta pendiente de XenoTherapeutics, la venta de activos de Gilead reconfigura el sentimiento de los inversionistas*

The share price fell to its lowest level so far this month today, with an intraday decline of 2.25%. Repare Therapeutics (RPTX) shares traded at a 12-month low amid ongoing uncertainty around its strategic direction. The biotech firm’s stock has been volatile following a $30 million asset sale to Gilead Sciences and a pending acquisition by XenoTherapeutics, which together have reshaped investor expectations.

The recent $25 million upfront payment from Gilead for RP-3467, Repare’s experimental cancer therapy, initially spurred a 20% premarket rally in early December. However, the stock has since retreated, pressured by skepticism over the pending $1.82-per-share cash offer from XenoTherapeutics. Analysts have highlighted the contingent value right (CVR) tied to future milestone payments as a potential upside, though its value remains uncertain.

The sale of RP-3467—now in a Phase 1 trial—has also raised questions about Repare’s remaining pipeline, which lacks commercial-stage assets.

Financial metrics underscore Repare’s precarious position. Despite a current ratio of 10.71 and $113 million in cash, the company reported a net margin of -608.26% and an Altman Z-Score of -1.03, signaling elevated bankruptcy risk. While the Gilead deal and acquisition provide near-term liquidity, analysts remain divided. TD Cowen downgraded the stock to “Hold,” citing CVR uncertainty, while H.C. Wainwright cut its price target to $3.00 but maintained a “Buy” rating. The outcome of the XenoTherapeutics acquisition vote in January 2026 and progress in RP-3467’s trial will be critical for near-term sentiment.